Last reviewed · How we verify

NewAmsterdam Pharma — Portfolio Competitive Intelligence Brief

NewAmsterdam Pharma pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Monotherapy ezetimibe Monotherapy ezetimibe phase 3 Cholesterol absorption inhibitor NPC1L1 (Niemann-Pick C1-Like 1) Cardiovascular
Monotherapy obicetrapib Monotherapy obicetrapib phase 3 CETP inhibitor CETP (cholesterol ester transfer protein) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amgen · 1 shared drug class
  2. Hoffmann-La Roche · 1 shared drug class
  3. Organon and Co · 1 shared drug class
  4. University of Oxford · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NewAmsterdam Pharma:

Cite this brief

Drug Landscape (2026). NewAmsterdam Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/newamsterdam-pharma. Accessed 2026-06-10.

Related